Teva Pharmaceutical Industries stock trades 4.36 percent below its yearly high
Published on 09/24/2026 at 02:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Teva Pharmaceutical Industries stock stood at USD 39.01 on the NYSE on September 23, 2026, 4.36 percent below its 52-week high of USD 40.79. On the same date, MarketBeat reported that Oppenheimer initiated coverage with an Outperform rating and a USD 50.00 price target.
Revenue reached USD 4.142 billion
Teva reported second-quarter 2026 revenue of USD 4,142,000,000, according to MarketBeat. That result was USD 160,000,000 higher than the USD 3,982,000,000 reported for the first quarter, an increase of 4.02 percent between the two 2026 periods.
The revenue comparison matters because the latest quarter also carried a weaker earnings profile. Teva's second-quarter operating profit was negative USD 231,000,000, compared with positive operating profit of USD 652,000,000 in the first quarter, while operating cash flow reached USD 411,000,000 in Q2.
Analyst target above the market price
Oppenheimer's USD 50.00 target stood USD 10.99 above the September 23 price of USD 39.01. The target therefore represented 28.17 percent above the reference price, while the stock remained 4.36 percent below its 52-week high.
The market value was USD 45,432,606,400 on September 23, 2026, with trading volume of 6,138,638 shares against an average volume of 5,291,268. The gap between current value and the yearly high leaves the analyst target as a separate valuation reference rather than a price description.
November date sets next checkpoint
Teva is scheduled to publish third-quarter 2026 results on November 3, 2026, at 7:00 a.m. ET, followed by a conference call at 8:00 a.m. ET, according to Quiver Quant. That date will provide the next periodized test of revenue growth and operating profitability.
Stock remains below yearly high
Teva Pharmaceutical Industries stock was trading at USD 39.01 on the NYSE on September 23, 2026, down USD 0.51 or 1.29 percent from the previous close. Its 52-week range was USD 18.21 to USD 40.79.
Teva Pharmaceutical Industries key data
- Company: Teva Pharmaceutical Industries Limited
- Ticker: TEVA
- Trading venue: NYSE
- Price as of September 23, 2026: USD 39.01
- Market capitalization: USD 45,432,606,400 as of September 23, 2026
- 52-week range: USD 18.21-40.79 as of September 23, 2026
- Sector / Industry: Healthcare / Drug Manufacturers - Specialty and Generic
- Next earnings date: November 3, 2026
